crystals Crystals Crystals Crystals 2073-4352 MDPI 10.3390/cryst2031248 crystals-02-01248 Short Note One-Pot Synthesis and Crystal Structure of Methyl 5-Hydroxy-1-phenyl-1H-pyrazole-3-carboxylate Saeed Aamer 1 * Arshad Ifzan 1 Flörke Ulrich 2 Department of Chemistry, Quaid-I-Azam University, Islamabad 45320, Pakistan; Email: ifzan_ash@hotmail.com Department of Inorganic and Analytical Chemistry, Universität Paderborn, Warburgerstr. 100, D-33098, Paderborn, Germany; Email: floerke@mail.upb.de Author to whom correspondence should be addressed; Email: aamersaeed@yahoo.com; Tel.: +92-51-9064-2128; Fax: +92-51-9064-2241. 27 08 2012 09 2012 2 3 1248 1252 15 05 2012 31 07 2012 14 08 2012 © 2012 by the authors; licensee MDPI, Basel, Switzerland. 2012

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

The title compound, Methyl 5-Hydroxy-1-Phenyl-1H-Pyrazole-3-Carboxylate (C11H10N2O3), was prepared by a one-pot, two-component reaction of an equimolar mixture of phenyl hydrazine and dimethyl acetylene dicarboxylate (DMAD) at reflux temperature for 2 h in a mixture of toluene and dichloromethane as solvent. C11H10N2O3 was crystallized from an ethanol solution in monoclinic space group P21/c with unit cell dimensions a = 9.5408(16), b = 9.5827(16), c = 11.580(2) Å, β = 105.838(3)°, V = 1018.5(3) Å3, Z = 4.

 pyrazole methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate crystal structure 1. Introduction

Over the years, pyrazoles have enjoyed a prominent place in heterocyclic chemistry largely due to the wide range of biological activity demonstrated by this class of compounds for uses such as pharmaceuticals and agricultural and veterinary drugs [1,2,3]. They possess anti-obesity [4], antianxiety [5] and HIV-1 reverse transcriptase inhibitor [6], anti-hyperglycemic, anti-pyretic, analgesic, anti-inflammatory and hypoglycemic activity [7,8]. Their derivatives are used as important intermediates in the preparation of drug molecules, as well as in the laboratory synthesis of natural products. The presence of ester functionality in pyrazoles further offers an attractive method for the generation of derivatives which may possess interesting medicinal and biological properties.

In this paper, we describe a new one pot synthesis and structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1a) which is a tautomeric form of methyl 5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylate (1b) (Figure 1). The tautomeric form 1a is predominant in a DMSO-d6 solution and this form also crystallizes from ethanol solution.

The structure of the tautomer 1b is found in the Cambridge database and is an organocatalyst for organic reactions [9].

Tautomeric forms of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate.

 2. Results and Discussion

Methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1) was prepared by refluxing a 1:1 molar ratio of phenyl hydrazine (2) and dimethylacetylene dicarboxylate (3) for 2 h, in a mixture of toluene and dichloromethane used as a solvent (Figure 2).

Synthesis of title compound 1.

The structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate was confirmed by 1H NMR spectra which revealed the presence of a singlet at δ 5.98 ppm assignable to 4-pyrazole H. Another singlet in the 1H NMR at δ 3.80 ppm is assigned to three protons of ester methoxy group. A singlet for hydroxyl proton appeared at δ 12.16 ppm. The FTIR showed peaks at 3204 cm−1 for OH stretching vibrations, and at 1728 cm−1 for the ester carbonyl in addition to other characteristic peaks.

Single crystals suitable for X-ray diffraction were obtained by recrystallization from ethanol. The molecular structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate is depicted in Figure 3.

The phenyl and the pyrazole ring planes are inclined at a dihedral angle dihedral angle of 60.83(5)°, the carboxylate group lies in the pyrazole plane with a C8-C9-C10-O2 torsion angle of 173.0(1)°. There are no unexpected geometric parameters. A closely related molecular structure 3-ethoxycarbonyl-1-phenyl-1H-pyrazol-5-yl 4-chlorobenzoate is known [10] with a 4-chlorobenzoate group replacing the –OH. Crystal packing shows strong O1–H…N2 (x, −y + 0.5, z + 0.5) interactions with H…N2 1.95 Å and O–H...N 167.9° that link the molecules into chains along the c axis. Weaker C2–H…O3 (−x + 2, −y + 1, −z) hydrogen bonds with H…O 2.42 Å and C–H…O 156.3° then connect these chains into centrosymemtric dimers (Figure 4).

The molecular structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1). Anisotropic displacement ellipsoids are drawn at the 50% probability level.

Crystal packing of 1 viewed along the b-axis with hydrogen bonding pattern shown as dashed lines. H atoms not involved in bonding are omitted.

 3. Experimental Section 3.1. General

The melting point was determined on a Stuart SMP3 melting point apparatus and is uncorrected. FT IR spectra were recorded using a Shimadzu IR 460 spectrophotometer by the Attenuated Total Reflectance (ATR) method. 1H NMR spectrum was determined as DMSO-d6 solution at 300 MHz using a Bruker AM-300 spectrophotometer. Mass Spectra (EI, 70 eV) were recorded on a GC-MS instrument and the elemental analysis was conducted using a LECO-183 CHNS analyzer.

3.2. Synthesis of Methyl 5-Hydroxy-1-phenyl-1<italic>H</italic>-pyrazole-3-carboxylate (1)

The title compound, C11H10N2O3, was prepared by stirring at reflux a mixture of phenyl hydrazine (0.22 g, 2 mmol) (2) and dimethylacetylene dicarboxylate (DMAD) (0.28 g, 2 mmol) (3) for 2 h in a 10 mL (1:1) mixture of toluene and DCM. The completion of reaction was monitored by thin layer chromatography. After completion the solvent was evaporated under reduced pressure and the white solid obtained were recrystallized from ethanol. m.p 188 °C. 1H NMR (300 MHz, DMSO-d6) δ 3.80 (3H, s), 5.98 (1H, s), 7.34–7.74 (5H, m), 12.16 (1H, s); FTIR (ATR): 3204, 1728, 1249 cm−1. Anal calcd. for C11H10N2O3: C, 60.55; H, 4.62; N, 12.84%; Found C, 60.49; H, 4.67; N, 12.78%.

 3.3. X-ray Structure Determination

C11H10N2O3, Mr = 218.2, crystal size 0.21 × 0.39 × 0.40 mm3, monoclinic, space group P21/c, a = 9.5408(16), b = 9.5827(16), c = 11.580(2) Å, b = 105.838(3)°, V = 1018.5(3) ų, Z = 4, ρcalc = 1.423 mg/cm3, μ = 0.106 mm−1, F(000) = 456. Data were collected at 130(2) K on a Bruker [11] AXS SMART APEX CCD diffractometer using MoKα radiation; 7713 reflections collected 2.22 < Θ < 27.88°.

The structure was solved by direct methods [12], and refined on F2 by full-matrix least-squares [12] with 147 parameters and 2402 unique intensities (Rint = 0.034). All non-hydrogen atoms were refined anisotropically. All H atom positions were clearly derived from difference Fourier maps and the refined on idealized positions with Uiso = 1.2 Ueq (C/O) or 1.5Ueq (Cmethyl, O), C–H distances of 0.95–0.98 Å and O–H 0.84 Å. The methyl H atoms were allowed to rotate but not to tip. CCDC-879881.

4. Conclusions

A highly efficient synthesis of compound 1 was carried out under mild conditions. The structure assignment as the methyl 5-hydroxy-1-phenyl-1H-3pyrazole-3-carboxylate tautomer was supported by 1H NMR data, elementary analysis and the crystallographic studies.

References Noga E.J. Barthalmus G.T. Mitchell M.K. Cyclic amines are selective cytotoxic agents for pigmented cells Cell Biol. Int. 1986 10 239 247 10.1016/0309-1651(86)90070-6 Subas M.S. Kristin M.L.D. Martha L.M. Bryson R. Andrei S. Robert J.R. David A.K. Hengmiao C. Jin L. Burton H.J. 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure–Activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog Bioorg. Med. Chem. Lett. 2006 16 288 292 10.1016/j.bmcl.2005.10.00616275075 Katritzky A.R. Wang M. Zhang S. Voronkov M.V. Regioselective synthesis of polysubstituted pyrazoles and isoxazoles J. Org. Chem. 2001 66 6787 6791 10.1021/jo010140711578235 Serena T. Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors Nutr. Metab. Cardiovasc. Dis. 2006 16 156 162 10.1016/j.numecd.2005.10.011 David J.W. Thomas C. Ronald R. James A.K. Hyacinth A. Duff D. Robert M. Thomas A.P. Kim T.Z. Thomas G.H. Lawrence D.W. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists Bioorg. Med. Chem. Lett. 1998 8 2067 2070 10.1016/S0960-894X(98)00372-29873487 Genin M.J. Biles C. Keiser B.J. Poppe S.M. Swaney S.M. Tarpley W.G. Romero D.L. Novel 1,5-diphenylpyrazole non nucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: Lead identification and SAR of 3- and 4-substituted derivatives J. Med. Chem. 2000 43 1034 1040 10.1021/jm990383f Cottineau P. Toto C. Marot A. Pipaud J.C. Synthesis and hypoglycemic evaluation of substituted pyrazole-4-carboxylic acids Bioorg. Med. Chem. Lett. 2002 12 2105 2108 10.1016/S0960-894X(02)00380-312127514 Lee K.Y. Kim J.M. Regioselective synthesis of 1,3,4,5-tetrasubstituted pyrazoles from Baylis–Hillman adducts Tetrahedron Lett. 2003 44 6737 6740 10.1016/S0040-4039(03)01648-4 Tzeng Z.H. Yang S.W. Liu P.M. Chen K.M. Optical resolution of 5-Oxo-1-phenyl-pyrazolidine-3-carboxylic acid as a new organocatalyst for organic reactions J. Chin. Chem. Soc. (Taipei) 2008 55 626 631 Zheng P.W. Fan M.L. Duan X.M. Li J.S. Huang P.M. 3-Ethoxycarbonyl-1-phenyl-1H-pyrazol-5-yl 4-chlorobenzoate Acta Cryst. 2006 E62 o311 o312 Bruker AXS Inc. SMART (Version 5.63),SAINT (Version 6.02) Bruker AXS Inc. Madison, WI, USA 2002 Sheldrick G.M. A short history of SHELX Acta Cryst. 2008 A64 112 122